The DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice
Open accessAbstract
Influenza viruses are respiratory pathogens of public health concern worldwide with up to 650,000 deaths occurring each year. Seasonal influenza virus vaccines are employed to prevent disease, but with limited effectiveness. Development of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is necessary for reducing influenza virus prevalence. In this study, we have utilized lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccines to intradermally deliver a combination of conserved influenza virus antigens (hemagglutinin stalk, neuraminidase, matrix-2 ion channel, and nucleoprotein) and induce strong immune responses with substantial breadth and potency in a murine model. The immunity conferred by nucleoside-modified mRNA-lipid nanoparticle vaccines provided protection from challenge with pandemic H1N1 virus at 500 times the median lethal dose after administration of a single immunization, and the combination vaccine protected from morbidity at a dose of 50 ng per antigen. The broad protective potential of a single dose of combination vaccine was confirmed by challenge with a panel of group 1 influenza A viruses. These findings support the advancement of nucleoside-modified mRNA-lipid nanoparticle vaccines expressing multiple conserved antigens as universal influenza virus vaccine candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a single mRNA vaccine can encode multiple antigens, strengthening the immune response against resilient pathogens7”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [7]
In the citing paper
“Another study used LNPs to deliver a 50 ng dose of nucleoside-modified mRNA encoding three conserved influenza proteins: neuraminidase, nucleoprotein and matrix-2 ion channel protein (Fig. 4) in addition to the haemagglutinin stalk7. Incredibly, this minuscule mRNA dose generated broadly protective antibodies and protected mice from an extraordinarily large viral challenge (500× LD50).”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [7]
Citations
Cites
The EMBL-EBI search and sequence analysis tools APIs in 2019
Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationEfficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationHobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,003
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Self-citationHemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C., Kanekiyo, M., Kong, W., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 700
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Advances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 592
Self-citation
Flagged first, then by citations
2 of the 67 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Self-citationmRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Alameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775
Self-citationNdeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Nanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582
Self-citationHuang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 537
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383
Self-citationIn vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
Rothgangl, T., Dennis, M. K., Lin, P. J. C., Oka, R., Witzigmann, D., Villiger, L., Qi, W., Hruzova, M., Kissling, L., Lenggenhager, D., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00933-4 · Cited by 378
Self-citationLaczko, D. I., Hogan, M. J., Toulmin, S. A., Hicks, P. D., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 355
Self-citationA multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Arevalo, C. P., Bolton, M. J., Sage, V. L., Ye, N., Furey, C., Muramatsu, H., Alameh, M., Pardi, N., Drapeau, E. M., Parkhouse, K., et al. (2022) · Science · doi:10.1126/science.abm0271 · Cited by 359
Self-citationMuramatsu, H., Lam, K., Bajusz, C., Laczkó, D., Karikó, K., Schreiner, P., Martin, A., Lutwyche, P., Heyes, J., & Pardi, N. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.001 · Cited by 331
Self-citationD614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.012 · Cited by 324
Self-citationmRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina‐Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 303
Self-citationCircular RNA vaccine in disease prevention and treatment
Niu, D., Wu, Y., & Lian, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01561-x · Cited by 281
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Pardi, N., & Krammer, F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01042-y · Cited by 252
Self-citationMelamed, J. R., Yerneni, S. S., Arral, M. L., LoPresti, S. T., Chaudhary, N., Sehrawat, A., Muramatsu, H., Alameh, M., Pardi, N., Weissman, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1444 · Cited by 218
Self-citationChimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
Martinez, D. R., Schäfer, A., Leist, S. R., la Cruz, G. D., West, A., Atochina‐Vasserman, E. N., Lindesmith, L. C., Pardi, N., Parks, R., Barr, M., et al. (2021) · Science · doi:10.1126/science.abi4506 · Cited by 175
Self-citationMolecular fate-mapping of serum antibody responses to repeat immunization
Schiepers, A., Wout, M. F. L. V. ’., Greaney, A. J., Zang, T. M., Muramatsu, H., Lin, P. J. C., Tam, Y. K., Mesin, L., Starr, T. N., Bieniasz, P. D., et al. (2023) · Nature · doi:10.1038/s41586-023-05715-3 · Cited by 166
Self-citationNanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 177
Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm
Wang, W., Feng, S., Ye, Z., Gao, H., Lin, J., & Ouyang, D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.021 · Cited by 173
Jain, S., Venkataraman, A. K., Wechsler, M. E., & Peppas, N. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114000 · Cited by 167
da Silva, J. R., Rodrigues, K. B., Pelegrin, G. F., Sales, N. S., Muramatsu, H., Silva, M. D. O., Porchia, B. F. M. M., Moreno, A. C. R., Aps, L. R. M. M., Venceslau-Carvalho, A. A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3464 · Cited by 155
Self-citationmRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent
Sajid, A., Matias, J., Arora, G., Kurokawa, C., DePonte, K., Tang, X., Lynn, G. E., Wu, M.-J., Pal, U., Strank, N. O., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9827 · Cited by 140
Self-citationDevelopment of multivalent mRNA vaccine candidates for seasonal or pandemic influenza
Chivukula, S., Plitnik, T., Tibbitts, T., Karve, S., Dias, A., Zhang, D., Goldman, R., Gopani, H., Khanmohammed, A., Sarode, A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00420-6 · Cited by 117
Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications
Leong, K. Y., Tham, S. K., & Poh, C. L. (2025) · Virology Journal · doi:10.1186/s12985-025-02645-6 · Cited by 139
PEDV-spike-protein-expressing mRNA vaccine protects piglets against PEDV challenge
Zhao, Y., Fan, B., Song, X., Gao, J., Guo, R., Cheng, Y., He, Z., Hu, H., Jiang, J., Zhao, L., et al. (2024) · mBio · doi:10.1128/mbio.02958-23 · Cited by 120
Wu, L., Li, X., Qian, X., Wang, S., Liu, J., & Yan, J. (2024) · Vaccines · doi:10.3390/vaccines12020186 · Cited by 137
Co-evolution of immunity and seasonal influenza viruses
Han, A. X., de Jong, S. P. J., & Russell, C. A. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00945-8 · Cited by 117
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111
Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery
Melamed, J. R., Hajj, K. A., Chaudhary, N., Strelkova, D., Arral, M. L., Pardi, N., Alameh, M., Miller, J. B., Farbiak, L., Siegwart, D. J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.022 · Cited by 101
Self-citationNucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena
Chavda, V. P., Hossain, M. M. M., Beladiya, J., & Apostolopoulos, V. (2021) · Biologics · doi:10.3390/biologics1030020 · Cited by 92
Carreño, J. M., Singh, G., Tcheou, J., Srivastava, K., Gleason, C., Muramatsu, H., Desai, P., Aberg, J. A., Miller, R. L., PARIS study group, et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.024 · Cited by 95
Self-citationHow COVID unlocked the power of RNA vaccines
Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-00019-w · Cited by 90
Saunders, K. O., Pardi, N., Parks, R., Santra, S., Mu, Z., Sutherland, L. L., Scearce, R. M., Barr, M., Eaton, A., Hernandez, G. E., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00307-6 · Cited by 91
Self-citationSynthetic modified messenger RNA for therapeutic applications
Gao, M., Zhang, Q., Feng, X.-H., & Liu, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.020 · Cited by 89
Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
Creytens, S., Pascha, M. N., Ballegeer, M., Saelens, X., & de Haan, C. A. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786617 · Cited by 88
Progress towards the Development of a Universal Influenza Vaccine
Wang, W.-C., Sayedahmed, E. E., Sambhara, S. R., & Mittal, S. K. (2022) · Viruses · doi:10.3390/v14081684 · Cited by 91
Pardi, N., Carreño, J. M., O’Dell, G., Tan, J., Bajusz, C., Muramatsu, H., Rijnink, W. F., Strohmeier, S., Loganathan, M., Bielak, D. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32149-8 · Cited by 87
Self-citationmRNA Vaccine Development for Emerging Animal and Zoonotic Diseases
Le, T., Sun, C., Chang, J., Zhang, G., & Yin, X. (2022) · Viruses · doi:10.3390/v14020401 · Cited by 99
Mallory, K. L., Taylor, J. A., Zou, X., Waghela, I. N., Schneider, C. G., Sibilo, M. Q., Punde, N. M., Perazzo, L., Savransky, T., Sedegah, M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00345-0 · Cited by 87
Self-citationMcMahon, M., O’Dell, G., Tan, J., Sárközy, A., Vadovics, M., Carreño, J. M., Puente‐Massaguer, E., Muramatsu, H., Bajusz, C., Rijnink, W. F., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206333119 · Cited by 81
Self-citationLipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 80
Self-citationLi, M., Jia, L., Xie, Y., Ma, W., Yan, Z., Liu, F., Deng, J., Zhu, A., Siwei, X., Su, W., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00732-9 · Cited by 81
mRNA vaccine sequence and structure design and optimization: Advances and challenges
Jin, L., Zhou, Y., Zhang, S., & Chen, S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108015 · Cited by 89
Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79
“Plasmid templates for in vitro transcription of antigenencoding RNAs were based on the previously published pUCccTEV-A101 vector (27).”
MethodSelf-citationFurey, C., Scher, G., Ye, N., Kercher, L., DeBeauchamp, J., Crumpton, J. C., Jeevan, T., Patton, C., Franks, J., Rubrum, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48555-z · Cited by 79
Self-citationHan, X., Xu, J., Xu, Y., Alameh, M., Xue, L., Gong, N., El-Mayta, R. D., Palanki, R., Warzecha, C. C., Zhao, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45537-z · Cited by 85
Self-citationmRNA vaccines: the most recent clinical applications of synthetic mRNA
Kwon, S., Kwon, M., Im, S., Lee, K., & Lee, H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01381-7 · Cited by 85
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
Li, D., Martinez, D. R., Schäfer, A., Chen, H., Barr, M., Sutherland, L. L., Lee, E., Parks, R., Mielke, D., Edwards, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33985-4 · Cited by 70
Self-citationHuang, P., Sun, L., Li, J., Wu, Q., Rezaei, N., Jiang, S., & Pan, C. (2023) · Cell Discovery · doi:10.1038/s41421-023-00571-x · Cited by 74
Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
Asr, M. H., Dayani, F., Segherloo, F. S., Kamedi, A., Neill, A. O., MacLoughlin, R. J., & Doroudian, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041127 · Cited by 73
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
Influenza and Universal Vaccine Research in China
Li, J., Zhang, Y., Zhang, X., & Liu, L. (2022) · Viruses · doi:10.3390/v15010116 · Cited by 74
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to NeutralizationPreprint
Weissman, D., Alameh, M., de Silva, T. I., Collini, P., Hornsby, H. R., Brown, R. L., LaBranche, C. C., Edwards, R. J., Sutherland, L. L., Santra, S., et al. (2020) · medRxiv · doi:10.1101/2020.07.22.20159905 · Cited by 72
Self-citationTreating Cystic Fibrosis with mRNA and CRISPR
Sanchez, A. D. S., Paunovska, K., Cristian, A., & Dahlman, J. E. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.137 · Cited by 75
Appelberg, S., John, L., Pardi, N., Végvári, Á., Bereczky, S., Ahlén, G., Monteil, V., Abdurahman, S., Mikaeloff, F., Beattie, M., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01568-21 · Cited by 68
Self-citationAdenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Coughlan, L., Kremer, E. J., & Shayakhmetov, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.034 · Cited by 67
Self-citationvan de Ven, K., Lanfermeijer, J., van Dijken, H., Muramatsu, H., de Melo, C. V. B., Lenz, S., Peters, F., Beattie, M. B., Lin, P. J. C., Ferreira, J. A., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9937 · Cited by 66
Self-citationmRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
Matarazzo, L., & Bettencourt, P. J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172691 · Cited by 68
Xiong, F., Zhang, C., Shang, B., Zheng, M., Wang, Q., Ding, Y., Luo, J., & Li, X. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2256422 · Cited by 60
Bacteria extracellular vesicle as nanopharmaceuticals for versatile biomedical potential
Ho, M. Y., Liu, S., & Xing, B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00434-5 · Cited by 62
Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L., Liu, L., Pan, X., Jia, W. W.-G., & Zhang, Y. (2023) · Viruses · doi:10.3390/v15081760 · Cited by 64
Hayashi, C. T. H., Cao, Y., Clark, L. C., Tripathi, A. K., Zavala, F. P., Dwivedi, G., Knox, J. J., Alameh, M., Lin, P. J. C., Tam, Y. K., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00577-8 · Cited by 60
Self-citationImmune Control of Avian Influenza Virus Infection and Its Vaccine Development
Dey, P., Ahuja, A., Panwar, J., Choudhary, P., Rani, S., Kaur, M., Sharma, A., Kaur, J. K., Yadav, A. K., Sood, V., et al. (2023) · Vaccines · doi:10.3390/vaccines11030593 · Cited by 65
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57
Ndeupen, S., Qin, Z., Jacobsen, S., Estanbouli, H., Bouteau, A., & Igyártó, B. Z. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.430128 · Cited by 57
Nucleic Acid-Based Technologies Targeting Coronaviruses
Le, T. K., Paris, C., Khan, K. S., Robson, F., Ng, W., & Rocchi, P. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.11.010 · Cited by 57
Lipid nanoparticle-based mRNA candidates elicit potent T cell responses
Zeng, Y., Escalona-Rayo, O., Knol, R. A., Kros, A., & Slütter, B. (2022) · Biomaterials Science · doi:10.1039/d2bm01581a · Cited by 54
Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications
Vadovics, M., Zhao, W., Daley, E. F., Lam, K., Daly, O. M., Rashid, K., Lee, H. R., Schreiner, P., Lundgreen, K. A., Gaudette, B. T., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01958-5 · Cited by 62
Self-citationRational development of a combined mRNA vaccine against COVID-19 and influenza
Ye, Q., Wu, M., Chao Hui, Z. H. O. U., Lu, X., Huang, B., Zhang, N., Zhao, H. J., Chi, H., Zhang, X., Ling, D., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00478-w · Cited by 51
B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat
Guthmiller, J. J., Utset, H. A., & Wilson, P. C. (2021) · Viruses · doi:10.3390/v13060965 · Cited by 56
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Messenger RNA chromatographic purification: advances and challenges
Xue, F., Su, Z. G., Cheng, Y., Ma, G., & Zhang, S. (2023) · Journal of Chromatography A · doi:10.1016/j.chroma.2023.464321 · Cited by 50
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines
Lim, C. M. L., Komarasamy, T. V., Adnan, N. A. A., Radhakrishnan, A. K., & Balasubramaniam, V. R. M. T. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13276 · Cited by 55
Yue, X., Zhong, C., Cao, R., Liu, S., Qin, Z., Liu, L., Zhai, Y., Luo, W., Lian, Y., Zhang, M., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00963-4 · Cited by 46
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Therapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 44
Ishaqat, A., & Herrmann, A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08484 · Cited by 42
Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
Broomfield, B. J., Tan, C. W., Qin, R. Z., Abberger, H., Duckworth, B. C., Alvarado, C., Dalit, L., Lee, C. L., Mugan, R. S., Mazrad, Z. A. I., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241148 · Cited by 42
Self-citationHatta, M., Hatta, Y., Choi, A., Hossain, J., Feng, C., Keller, M. W., Ritter, J. M., Huang, Y., Fang, E., Pusch, E. A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ads1273 · Cited by 42
Self-citationSynthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside
Ding, S., Alexander, E., Liang, H., Kulchar, R. J., SINGH, R. K., Herzog, R. W., Daniell, H., & Leong, K. W. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00482 · Cited by 43
Knudson, C. J., Alves-Peixoto, P., Muramatsu, H., Stotesbury, C., Tang, L., Lin, P. J. C., Tam, Y. K., Weissman, D., Pardi, N., & Sigal, L. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.011 · Cited by 39
Self-citationThe potential of mRNA vaccines in cancer nanomedicine and immunotherapy
Pan, S., Fan, R., Han, B. R., Tong, A., & Guo, G. F. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.11.003 · Cited by 39
Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
Kerstetter, L. J., Buckley, S., Bliss, C. M., & Coughlan, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607333 · Cited by 42
Self-citationThe Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination
Rajendran, M., Krammer, F., & McMahon, M. (2021) · Vaccines · doi:10.3390/vaccines9080846 · Cited by 38
Self-citationRational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 45
Zhu, W. S., Wei, L., Dong, C., Wang, Y., Kim, J. H., Ma, Y., Gonzalez, G. X., & Wang, B. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.024 · Cited by 38
Current vaccine approaches and emerging strategies against herpes simplex virus (HSV)
Wijesinghe, V. N., Farouk, I. A., Zabidi, N. Z., Puniyamurti, A., Choo, W. S., & Lal, S. K. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1960162 · Cited by 37
Rcheulishvili, N., Mao, J., Papukashvili, D., Liu, C., Wang, Z., Zhao, J., Xie, F., Pan, X., Ji, Y., He, Y., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.066 · Cited by 41
Nanocarrier vaccine therapeutics for global infectious and chronic diseases
Simnani, F. Z., Singh, D., Patel, P., Choudhury, A., Sinha, A., Nandi, A., Samal, S. K., Verma, S. K., & Panda, P. K. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.008 · Cited by 38
mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy
Haghmorad, D., Eslami, M., Orooji, N., Halabitska, I., Kamyshna, I. I., Kamyshnyi, O., & Oksenych, V. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1547025 · Cited by 42
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice
Freyn, A. W., Pine, M., Rosado, V. C., Benz, M., Muramatsu, H., Beattie, M. B., Tam, Y. K., Krammer, F., Palese, P., Nachbagauer, R., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.003 · Cited by 37
Self-citationKorzun, T., Moses, A. S., Diba, P., Sattler, A. L., Taratula, O. R., Sahay, G., Taratula, O., & Marks, D. L. (2023) · Pharmaceuticals · doi:10.3390/ph16081088 · Cited by 40
Puente‐Massaguer, E., Vasilev, K., Beyer, A., Loganathan, M., Francis, B., Scherm, M. J., Arunkumar, G. A., González‐Domínguez, I., Zhu, X., Wilson, I. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi4753 · Cited by 36
Self-citationSeasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection
Kackos, C. M., DeBeauchamp, J., Davitt, C. J. H., Lonzarić, J., Sealy, R. E., Hurwitz, J. L., Samsa, M. M., & Webby, R. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00752-5 · Cited by 38
Metadata
- Authors
- Freyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., Krammer, F., Coughlan, L., Palese, P., Pardi, N., & Nachbagauer, R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- University of Pennsylvania (US)
- Acuitas Therapeutics (Canada) (CA)
- Corresponding author
- Pardi, Norbert
- Nachbagauer, Raffael
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 28
- Issue
- 7
- Pages
- 1569-1584
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC7335735
- OpenAlex
- W3016394521
- Cited by
- 299
- References
- 67
- Citations by year
- 2026: 25 · 2025: 58 · 2024: 50 · 2023: 55 · 2022: 58 · 2021: 44 · 2020: 9
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2019/01523-3)
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI07647, 5P01AI097092-07, 75N93019C00051, R01-AI146101-01)
- U.S. Public Health Service (AI07647, 5P01AI097092-07)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- universal influenza vaccine, nucleoside-modified mRNA, lipid nanoparticle vaccine, multi-antigen vaccine, hemagglutinin stalk, neuraminidase, matrix protein 2, nucleocapsid protein, pandemic H1N1, immunological cross-reactivity, intradermal drug delivery
- MeSH terms
- mRNA Vaccines, Animals, Antibodies, Viral, Antigens, Viral, Disease Models, Animal, Influenza Vaccines, Injections, Intradermal, Liposomes, Neuraminidase, Nucleosides, Orthomyxoviridae Infections, Vaccines, Synthetic, Hemagglutinin Glycoproteins, Influenza Virus, Nucleocapsid Proteins, NIH 3T3 Cells, Mice, Influenza A Virus, H1N1 Subtype, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
